Medical Oncology

Adverse Events

Questions discussed in this category

When, if ever, do you incorporate a dental evaluation before initiating Dato-DXd to offer guidance on oral care and help limit oral toxicity?

How should this differ from evaluations done for bisphosphonates/denosumab, for example?

2 Answers available

How does your management of stomatitis from Dato-DXd compare to your approach for stomatitis from other cancer-directed treatments?

3 Answers available

What strategies can we use to help patients receiving Dato-DXd report symptoms earlier, with the goal of early intervention to prevent progression to higher grade side effects?

3 Answers available

How should Dato-DXd be managed in the absence of necessary resources for ocular exams and referrals?

What is the ideal timing and frequency of referrals for exams? What is the bare minimum if access is limited?

3 Answers available

Is it safe to give thoracic irradiation to a patient with lung cancer previously treated with a VEGF inhibitor?

I've read about patients who were treated with concurrent bevacizumab-RT who developed lethal tracheoesophageal fistulas. How long would you have to w...

1 Answer available

Papers discussed in this category

International journal of radiation oncology, biology, physics, 2013-09-01

Increased bowel toxicity in patients treated with a vascular endothelial growth factor inhibitor (VEGFI) after stereotactic body radiation therapy (SBRT).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024 Sep 12

Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01.

Cancer treatment reviews, 2024 Mar 11

Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024 Apr 23

Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study.

The Oncologist, 2025 Mar 10

Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis.

Medicina oral, patologia oral y cirugia bucal, 2016 Mar 01

Prevention of medication-related osteonecrosis of the jaws secondary to tooth extractions. A systematic review.

Medical Oncology

Adverse Events

Questions discussed in this category

Papers discussed in this category

Related Topics in Medical Oncology